Cyclerion Therapeutics Stock (NASDAQ:CYCN)
Previous Close
$2.95
52W Range
$1.75 - $5.25
50D Avg
$2.79
200D Avg
$2.92
Market Cap
$7.14M
Avg Vol (3M)
$11.44K
Beta
1.91
Div Yield
-
CYCN Company Profile
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018 for the treatment of disorders of the CNS. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
CYCN Performance
Peer Comparison
Ticker | Company |
---|---|
SNTI | Senti Biosciences, Inc. |
ZVSA | ZyVersa Therapeutics, Inc. |
MGTA | Dianthus Therapeutics, Inc. |
XFOR | X4 Pharmaceuticals, Inc. |
CFRX | ContraFect Corporation |
AXLA | Axcella Health Inc. |
MNPR | Monopar Therapeutics Inc. |
ACHL | Achilles Therapeutics plc |
LRMR | Larimar Therapeutics, Inc. |
ERAS | Erasca, Inc. |
FENC | Fennec Pharmaceuticals Inc. |
SGTX | Sigilon Therapeutics, Inc. |
KRON | Kronos Bio, Inc. |
SONN | Sonnet BioTherapeutics Holdings, Inc. |
LIPO | Lipella Pharmaceuticals Inc. |
ADXN | Addex Therapeutics Ltd |
KZR | Kezar Life Sciences, Inc. |
FBRX | Forte Biosciences, Inc. |
CDIO | Cardio Diagnostics Holdings, Inc. |